Fresenius Medical Care

$32.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.06 (-0.19%) Today
$0.00 (0.00%) As of 4:14 PM EDT after-hours

Why Robinhood?

You can buy or sell FMS and other stocks, options, ETFs, and crypto commission-free!

About FMS

Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. Read More It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Employees
—
Headquarters
Bad Homburg, Hessen
Founded
2006
Market Cap
19.25B
Price-Earnings Ratio
14.55
Dividend Yield
1.40
Average Volume
771.09K
High Today
$32.67
Low Today
$32.09
Open Price
$32.49
Volume
372.71K
52 Week High
$42.75
52 Week Low
$29.17

Collections

FMS News

New York TimesApr 1

Fresenius Medical Care Working With Dialysis Providers in U.S. to Tackle Coronavirus

BERLIN — Fresenius Medical Care (FMC) on Wednesday said it was working with other dialysis providers to provide care in isolation for people with kidney problem
17
ReutersMar 31

BRIEF-Cytosorb Gets Marketing Approval In Mexico

March 31 (Reuters) - Cytosorbents Corp: * CYTOSORB® RECEIVES MARKETING APPROVAL IN MEXICO WITH COMMERCIALIZATION TO COMMENCE WITH PARTNER FRESENIUS MEDICAL CAR
6
BenzingaMar 31

CytoSorb® Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care

MONMOUTH JUNCTION, N.J., March 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO) a critical care immunotherapy leader commercializing its CytoSorb
47

FMS Earnings

$0.00
$0.51
$1.01
$1.52
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Estimated
— per share
Actual
Available May 6, Pre-Market

People Also Bought

You May Also Like

Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.